Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Mizzen seismic re-processing contract awarded

24 Oct 2012 07:00

RNS Number : 3724P
Fastnet Oil & Gas PLC
24 October 2012
 



24 October 2012

 

Fastnet Oil & Gas plc

 

Mizzen Basin seismic re-processing contract awarded

 

Fastnet Oil and Gas plc ("Fastnet" or the "Company") (AIM: FAST, ESM: FOI), the recently listed E&P company focussed on near term exploration acreage in the Celtic Sea and Africa, is pleased to announce that its wholly-owned subsidiary, Fastnet Oil and Gas Ireland Ltd, has signed an agreement with WesternGeco Seismic Holdings Ltd ("WesternGeco"), the world's leading geophysical services company, (part of Schlumberger) to provide specialist reprocessing of key prospect-defining 2D seismic data across the Company's Mizzen Basin licence option area, in the North Celtic Sea, as well as amplitude versus offset and rock physics work. It is expected that this work will be completed early in 2013.

 

Cathal Friel, Chairman of Fastnet, commented:

"I am very pleased we have been able to contract WesternGeco to undertake this 2D seismic reprocessing programme, they are one of the most respected companies in the space and through their work we hope to continue de-risking the licence area in order to mature it toward exploratory drilling. I look forward to announcing the results of this work as soon as is practicable." 

 

- Ends -

 

For further information contact:

 

Fastnet Oil & Gas plc

Cathal Friel, Non-Executive Chairman

Steve Staley, CEO

+353 (1) 644 0007

Shore Capital

(Nominated Adviser & Joint Broker)

Nomad

Bidhi Bhoma

Edward Mansfield

 

Corporate Broking

Jerry Keen

+44 (0) 20 7408 4090

Davy

(ESM Adviser & Joint Broker)

John Frain

Brian Garrahy

Roland French

 

+353 (1) 679 6363

FTI Consulting

Billy Clegg

Edward Westropp

+44 (0) 207 831 3113

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ISEBKNDBOBDDBKB
Date   Source Headline
4th Mar 202112:00 pmRNSAmryt Announces Record FY 2020 Results
25th Feb 20217:00 amRNSAmryt Supports Global Rare Disease Day 2021
24th Feb 20217:00 amGNWAmryt to Announce Q4 and FY 2020 Results on Thursday March 4, 2021
10th Feb 20217:00 amRNSAmryt to Present at SVB Leerink Conference
4th Feb 20217:00 amGNWAmryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel
20th Jan 20217:00 amGNWAmryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
6th Jan 20217:00 amRNSAmryt to present at H.C Wainwright Conference
23rd Dec 20207:00 amGNWAmryt Granted Orphan Drug Designation by the FDA for AP103
17th Dec 20207:00 amGNWAmryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
11th Dec 202010:00 amGNWHolding(s) in Company
9th Dec 20202:45 pmGNWHolding(s) in Company
9th Dec 20207:00 amGNWAmryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil
8th Dec 20207:00 amGNWAmryt Announces $40m Private Placement with Leading Biotech Investors
5th Nov 202012:00 pmGNWAmryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance
29th Oct 20207:00 amGNWAMRYT ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA
19th Oct 20207:00 amGNWAmryt and Swixx Sign Distribution Deal for Lojuxta
14th Oct 20207:00 amRNSAMRYT TO ANNOUNCE Q3 RESULTS ON NOVEMBER 5, 2020
14th Oct 20207:00 amGNWNotice of Results
12th Oct 202011:00 amGNWHolding(s) in Company
9th Oct 20207:00 amGNWVirtual Analyst & Investor Event - Tuesday November 3, 2020
8th Oct 20207:00 amGNWAMRYT TO PRESENT EASE TRIAL DATA BY LATE-BREAKING PRESENTATION AT EADV ON OCTOBER 31, 2020
1st Oct 20207:00 amGNWExercise of Options and Total Voting Rights
30th Sep 202012:30 pmGNWHolding(s) in Company
23rd Sep 20207:00 amRNSAMRYT SUPPORTS GLOBAL FH AWARENESS DAY
21st Sep 202011:00 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
15th Sep 20207:00 amRNSPOSITIVE OPINION ON AP103 ORPHAN DRUG DESIGNATION
9th Sep 20202:05 pmRNSSecond Price Monitoring Extn
9th Sep 20202:00 pmRNSPrice Monitoring Extension
9th Sep 20207:00 amRNSPOSITIVE TOP LINE RESULTS FROM PHASE 3 TRIAL IN EB
11th Aug 202011:09 amRNSCANCELLATION OF ADMISSION TO EURONEXT GROWTH
7th Aug 20207:00 amRNSAMRYT PRESENTING AT CANACCORD GENUITY CONFERENCE
6th Aug 202012:00 pmRNSAMRYT ANNOUNCES Q2 2020 RESULTS
29th Jul 20202:30 pmRNSResult of AGM
29th Jul 20207:00 amRNSAMRYT HOSTING KOL CALL ON EB DISEASE LANDSCAPE
20th Jul 20207:00 amRNSAMRYT TO ANNOUNCE Q2 RESULTS ON AUGUST 6, 2020
15th Jul 20208:00 amRNSEuronext Growth Dublin Notice
10th Jul 20207:00 amRNSExercise of Warrants & Issue of Ordinary Shares
8th Jul 20203:09 pmRNSAMRYT LISTED ON NASDAQ & CEO TO RING CLOSING BELL
30th Jun 20207:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
24th Jun 20207:00 amRNSForm F-1 publicly filed for impending US listing
4th Jun 20202:20 pmRNSDirector/PDMR Shareholding
3rd Jun 202011:30 amRNSDirector/PDMR Shareholding
3rd Jun 20207:00 amRNSAMRYT & SWIXX SIGN DISTRIBUTION DEAL FOR MYALEPTA
11th May 20207:00 amRNSQ1 2020 RESULTS
11th May 20207:00 amRNSFY 2019 RESULTS
7th May 20209:00 amRNSNotice of Results
7th May 20207:00 amRNSFILSUVEZ® CONFIRMED AS GLOBAL BRAND NAME FOR AP101
23rd Apr 20207:00 amRNSEASE CLINICAL STUDY UPDATE
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20207:00 amRNSMarket Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.